Jurubita 2012.

Study characteristics
Methods	Study design: parallel, open‐label RCT Study duration: before 2012 Duration of follow‐up: 12 months
Participants	Setting: single centre country: Romania Inclusion criteria: biopsy‐proven IMN with persistent heavy proteinuria (> 8 g/day, minimum 6 months) Baseline characteristics Pathology stage: not reported Mean proteinuria, range (g/24 hours): treatment group 1 (10.4, 8.4 to 14.9); treatment group 2 (10.26, 8 to 14.1) GFR (mL/min/1.73 m²): > 60 Baseline declining kidney function: not reported Previous immunosuppressive status: not reported Number: treatment group 1 (9); treatment group 2 (9) Mean age ± SD (years): not reported Sex: not reported Exclusion criteria: not reported
Interventions	Treatment group 1 MMF: 1 g/day CSA: 2 mg/kg/day, but not exceeding 150 mg/day Prednisolone: 0.15 mg/kg/day Duration: 12 months Treatment group 2 CSA: 5 mg/kg/day, but not exceeding 150 mg/day Prednisolone: 0.15 mg/kg/day Co‐interventions Use of ACEi or ARB during follow‐up: not reported
Outcomes	Partial or complete remission
Notes	Funding information: not reported Only abstract was available and unpublished data were not used
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	No patient was lost to follow‐up, and an intention‐to‐treat analysis was used
Selective reporting (reporting bias)	High risk	Only remission data were provided in the abstract
Other bias	Unclear risk	Only abstract was available and unpublished data were not used